Lonza Group AG Logo

Lonza Group AG

A leading CDMO for pharma, biotech & nutrition, providing end-to-end development & manufacturing.

LONN | SW

Overview

Corporate Details

ISIN(s):
CH0013841017 (+2 more)
LEI:
549300EFW4H2TCZ71055
Country:
Switzerland
Address:
MÜNCHENSTEINERSTR. 38, 4052 BASEL
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Lonza Group AG is a Swiss multinational company and a leading global Contract Development and Manufacturing Organization (CDMO) serving the pharmaceutical, biotechnology, and nutrition industries. The company provides integrated services that span from early-stage development to the commercial manufacturing of drug substances and drug products. Lonza specializes in a wide range of advanced technologies, including mammalian and microbial biologics, small molecules, highly potent active pharmaceutical ingredients (APIs), bioconjugates, mRNA, and cell and gene therapies. Founded in 1897, Lonza leverages its extensive scientific and manufacturing expertise to enable its customers to bring innovative and life-enhancing therapies to market for patients worldwide.

Social Media

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-10-23 06:30
Earnings Release
Lonza Delivers a Strong Q3 2025 and Confirms Full-Year 2025 Outlook for its CDM…
English 18.3 KB
2025-10-23 02:00
Earnings Release
Lonza Delivers a Strong Q3 2025 and Confirms Full-Year 2025 Outlook for its CDM…
English 15.5 KB
2025-10-03 09:00
Board/Management Information
Lonza Nominates Claudia Sussmuth-Dyckerhoff as Board Member
English 17.8 KB
2025-10-03 02:00
Board/Management Information
Lonza Nominates Claudia Süssmuth-Dyckerhoff as Board Member
English 14.2 KB
2025-09-12 09:00
Board/Management Information
Lonza Appoints Jason Berndt as Head of Group Operations, and Maria Soler Nunez …
English 22.8 KB
2025-09-12 02:00
Board/Management Information
Lonza Appoints Jason Berndt as Head of Group Operations, and Maria Soler Nunez …
English 18.8 KB
2025-07-23 06:30
Earnings Release
Lonza Delivers Strong H1 2025 Performance and Upgrades 2025 Full-Year CDMO Sale…
English 42.2 KB
2025-07-23 02:00
Earnings Release
Lonza Delivers Strong H1 2025 Performance and Upgrades 2025 Full-Year CDMO Sale…
English 37.0 KB
2025-07-23 02:00
Earnings Release
Lonza erzielt starkes Ergebnis im ersten Halbjahr 2025 und erhöht Umsatz- und M…
German 36.9 KB
2025-05-27 07:00
Earnings Release
Lonza Publishes 2024 Comparative Financials Under One Lonza Organizational Stru…
English 12.7 KB
2025-05-27 02:00
Regulatory Filings
Lonza Publishes 2024 Comparative Financials Under One Lonza Organizational Stru…
English 9.7 KB
2025-05-15 09:00
Board/Management Information
Lonza Appoints Andreas Bohrer as Chief Legal & Corporate Affairs Officer
English 14.6 KB
2025-05-15 02:00
Board/Management Information
Lonza Appoints Andreas Bohrer as Chief Legal & Corporate Affairs Officer
English 11.0 KB
2025-05-10 16:30
AGM Information
Lonza Announces Results of the 2025 Annual General Meeting All Motions Propose…
English 16.3 KB
2025-05-09 06:30
Earnings Release
Lonza Q1 2025 Qualitative Update: Strong Performance Across All Businesses in L…
English 15.2 KB

Automate Your Workflow. Get a real-time feed of all Lonza Group AG filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Lonza Group AG

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for Lonza Group AG via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
2025-03-14 N/A Executive member Buy None 147,442.00 CHF
2025-03-13 N/A Executive member Buy None 107,906.00 CHF
2025-03-12 N/A Executive member Buy None 146,239.00 CHF
2025-03-11 N/A Executive member Buy None 382,476.00 CHF
2025-03-10 N/A Executive member Buy None 771,722.40 CHF
2025-03-07 N/A Executive member Buy None 338,476.00 CHF
2025-03-06 N/A Executive member Buy None 313,416.00 CHF
2025-02-18 N/A Executive member Buy None 164,554.00 CHF
2025-02-14 N/A Executive member Buy None 130,606.00 CHF
2025-02-13 N/A Executive member Buy None 29,500.00 CHF

Peer Companies

Traws Pharma, Inc. Logo
Develops oral small-molecule therapies for respiratory viral diseases and cancer.
United States of America
TRAW
Trevi Therapeutics, Inc. Logo
Clinical-stage biopharma developing an oral therapy for chronic cough in IPF and RCC.
United States of America
TRVI
TRINITY BIOTECH PLC Logo
Develops and markets clinical diagnostic test kits and biosensors for labs and point-of-care.
United States of America
TRIB
TSUMURA & CO. Logo
A leader in Japanese Kampo herbal medicine, producing prescription and OTC formulations.
Japan
4540
TURK İLAÇ VE SERUM SANAYİ A.Ş. Logo
Turkish producer of pharmaceuticals, specializing in IV solutions and vaccines for hospitals.
Türkiye
TRILC
Tvardi Therapeutics, Inc. Logo
Developing oral STAT3 inhibitors to treat cancers and fibrosis-driven diseases.
United States of America
TVRD
UCB Logo
UCB
Biopharma firm developing treatments for severe neurological and immunological diseases.
Belgium
UCB
Ultragenyx Pharmaceutical Inc. Logo
Develops and commercializes novel therapies for rare and ultra-rare genetic diseases.
United States of America
RARE
Develops biopharma therapies for endocrinology, ophthalmology, and dermatology needs.
Hong Kong
690
Unicycive Therapeutics, Inc. Logo
A clinical-stage biotech developing novel treatments for kidney diseases, led by oxylanthanum carbonate.
United States of America
UNCY

Talk to a Data Expert

Have a question? We'll get back to you promptly.